MedPath

Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects

Not Applicable
Conditions
Normal Tension Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Interventions
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Device: Dynamic Vessel Analyzer (DVA)
Device: Pattern Electroretinography (pERG)
Device: Optical coherence tomography (OCT)
Device: Laser Speckle Flowgraphy (LSFG)
Registration Number
NCT03870230
Lead Sponsor
Medical University of Vienna
Brief Summary

Glaucoma is characterized by a progressive loss of retinal ganglion cells (RGCs) leading to optic nerve head (ONH) damage and associated visual field defects. The main risk factor for glaucoma is elevated intraocular pressure (IOP). Reducing IOP slows down the progression of the disease as several large multicenter trials have shown. Some patients, however, still progress despite adequately controlled IOP. As such, there is considerable interest in approaches that rescue RGCs independent of IOP, a strategy called neuroprotection. Although this field was actively discovered in the last 20 years in the brain and the eye, no non-IOP related treatment is clinically available to date. Various approaches are currently studied in some detail. One interesting strategy focuses on the neurovascular unit.

The blood flow of the human retina is controlled by complex mechanisms that include myogenic, metabolic and hormonal factors. The high consumption of oxygen in the human retina is crucial for normal functioning of the organ. As in the brain, blood flow in the retina is also controlled by neurovascular coupling. This means that the retina increases its blood flow to regions in which neurons are activated. This is done in an effort to provide more oxygen and glucose to the active neurons. In the recent years evidence has accumulated that astrocytes play a key role in mediating this vasodilator signal.

In the brain, abnormalities in neurovascular coupling have been observed in diseases like stroke, hypertension, spinal-cord injury and Alzheimer's disease. This break-down of neurovascular coupling is considered to play a key role in neuronal death in these diseases. In the retina, abnormalities in neurovascular coupling have been observed in diseases as diabetes and glaucoma.

Most of the data obtained in the human retina stem from a system that measures retinal vasodilatation during stimulation with flickering light. The investigators have previously shown that flicker stimulation of the retina is, however, also associated with a pronounced increase in retinal blood velocities. In this study the investigators employed laser Doppler velocimetry (LDV) for the measurement of retinal blood velocities, but this technique is not clinically applicable because it requires excellent fixation of the subject under study. In the present study, the investigators propose to use an alternative system for neurovascular coupling that they have developed recently. In this approach, the investigators use bi-directional Fourier-domain optical coherence tomography for the assessment of retinal blood flow. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology, OCT has become a standard tool in visualizing the retina and nowadays is considered also as a standard tool in the diagnosis of retinal disease. In the recent years, conventional time domain OCT was replaced by Fourier domain OCT providing significantly improved signal quality.

This bidirectional system overcomes the limitations of previously realized techniques, which include doubtful validity and limited reproducibility. In addition, pattern ERG, multifocal ERG and oscillatory potentials will be measured to allow for concomitant assessment of neural function.

The investigators seek to measure neurovascular coupling in the human retina in patients with early primary open angle glaucoma (POAG), normal tension glaucoma, ocular hypertension and a healthy control group. In order to obtain information on neurovascular coupling, both neuronal function as well as retinal blood flow need to be measured. In the present study, the investigators will employ pattern ERG, multifocal ERG as well as oscillatory potentials to assess the function of the inner retina. Retinal blood flow through major retinal arterial and venous branch vessels will be measured before, during and after flicker stimulation with the dual-beam bidirectional Fourier Domain Doppler OCT coupled to the commercially available Dynamic Vessel Analyzer (DVA) produced by IMEDOS, Jena, Germany, which provides adequate resolution to study the retinal circulation.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
POAG MD>10dBLaser Speckle Flowgraphy (LSFG)patients with primary open angle glaucoma with MD in visual field more than 10dB
POAG MD<10dBPattern Electroretinography (pERG)patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
POAG MD>10dBOptical coherence tomography (OCT)patients with primary open angle glaucoma with MD in visual field more than 10dB
POAG MD<10dBFourier Domain Doppler Optical Coherence Tomography (FDOCT)patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
POAG MD<10dBDynamic Vessel Analyzer (DVA)patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
POAG MD>10dBDynamic Vessel Analyzer (DVA)patients with primary open angle glaucoma with MD in visual field more than 10dB
NTG MD<10dBFourier Domain Doppler Optical Coherence Tomography (FDOCT)patients with normal tension glaucoma with MD in visual field less than or equal 10dB
NTG MD>10dBDynamic Vessel Analyzer (DVA)patients with normal tension glaucoma with MD in visual field more than 10dB
POAG MD<10dBOptical coherence tomography (OCT)patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
POAG MD<10dBLaser Speckle Flowgraphy (LSFG)patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
NTG MD<10dBOptical coherence tomography (OCT)patients with normal tension glaucoma with MD in visual field less than or equal 10dB
OHTDynamic Vessel Analyzer (DVA)patients with ocular hypertension
OHTPattern Electroretinography (pERG)patients with ocular hypertension
OHTLaser Speckle Flowgraphy (LSFG)patients with ocular hypertension
controlsDynamic Vessel Analyzer (DVA)healthy, age and sex matched, control subjects
POAG MD>10dBFourier Domain Doppler Optical Coherence Tomography (FDOCT)patients with primary open angle glaucoma with MD in visual field more than 10dB
POAG MD>10dBPattern Electroretinography (pERG)patients with primary open angle glaucoma with MD in visual field more than 10dB
NTG MD<10dBDynamic Vessel Analyzer (DVA)patients with normal tension glaucoma with MD in visual field less than or equal 10dB
NTG MD<10dBPattern Electroretinography (pERG)patients with normal tension glaucoma with MD in visual field less than or equal 10dB
NTG MD<10dBLaser Speckle Flowgraphy (LSFG)patients with normal tension glaucoma with MD in visual field less than or equal 10dB
NTG MD>10dBPattern Electroretinography (pERG)patients with normal tension glaucoma with MD in visual field more than 10dB
NTG MD>10dBOptical coherence tomography (OCT)patients with normal tension glaucoma with MD in visual field more than 10dB
OHTFourier Domain Doppler Optical Coherence Tomography (FDOCT)patients with ocular hypertension
controlsFourier Domain Doppler Optical Coherence Tomography (FDOCT)healthy, age and sex matched, control subjects
controlsOptical coherence tomography (OCT)healthy, age and sex matched, control subjects
NTG MD>10dBFourier Domain Doppler Optical Coherence Tomography (FDOCT)patients with normal tension glaucoma with MD in visual field more than 10dB
NTG MD>10dBLaser Speckle Flowgraphy (LSFG)patients with normal tension glaucoma with MD in visual field more than 10dB
OHTOptical coherence tomography (OCT)patients with ocular hypertension
controlsPattern Electroretinography (pERG)healthy, age and sex matched, control subjects
controlsLaser Speckle Flowgraphy (LSFG)healthy, age and sex matched, control subjects
Primary Outcome Measures
NameTimeMethod
Flicker induced blood flow alterations1 day

Response of retinal blood flow to flicker light

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Clinical Pharmacology, Medical University of Vienna

🇦🇹

Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath